# 3.3.1.2 Cases with Grade 4 Infections

**Page range:** 46–47

```text
3.3.1.2
Cases with Grade 4 Infections
A total of 43 cases reporting 47 life-threatening AEs14 or Grade 4 severity were retrieved
from the Company Safety Database.
An overview of characteristics of these cases reporting life-threatening infections is
presented in Table 15.
Table 15 Summary of Characteristics of Cases Involving the Use of
Pralsetinib and Reporting Life-threatening Infections from the
Safety Database (N=43)
Characteristic
Number of Cases (%)
Primary Reporter Type
Healthcare Professional
32 (74.4)
Non-Healthcare
Professional/Consumer
11 (25.6)
Sex
Male
24 (55.8)
Female
18 (41.9)
Not reported
1 (2.3)
Age (Years)
Range: 13 to 81
Mean: 59.2
Median: 60.5
< 18 (Pediatric)
1 (2.3)
18 to 64 (Adult)
27 (62.8)
65 (Elderly)
15 (34.9)
Source
Clinical Study
34 (79)
Non-Interventional
Study/Program
3 (7)
Spontaneous
5 (11.6)
Literature Study
1 (2.3)
Indication groups
Lung cancer
25 (58.1)
Thyroid cancer
15 (34.9)
Other malignancies
3 (7)
MedDRA version 27.0
The below Table 16 presents overview of these life-threatening infections by MedDRA
PT.

13 AER 3172766, AER 3313491, AER 3355432, AER 3355845 and AER 3428340.
14 Along with 16 events of infections reported with severity as Grade 5 (n=4), Grade 3 (n=7), Grade 2 (n=3)
and not reported (n=2).

47
Drug Safety Report No: 1132062
Table 16 Distribution of Grade 4 Infections by MedDRA PT from the Safety
Database (n=47)
Preferred Term
Count
Sepsis
13 (27.7)
Pneumonia
10 (21.3)
Pneumocystis jirovecii pneumonia
3 (6.4)
Septic shock, Urinary tract infection,
Neutropenic sepsis
```